{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:56:37Z","timestamp":1760316997966,"version":"build-2065373602"},"reference-count":46,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2002,5,23]],"date-time":"2002-05-23T00:00:00Z","timestamp":1022112000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2002,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>To evaluate the efficacy and toxicity of cisplatin, tegafur, and leucovorin as neoadjuvant chemotherapy (CT) for patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck (SCCHN).<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Patients with SCCHN according to World Health Organization (WHO) performance status of 2 or less and adequate organ function were enrolled. The CT regimen (PTL) was 50 mg\/m<jats:sup>2<\/jats:sup> cisplatin (P) on Day 1, 800 mg per day oral tegafur (T), and 60 mg per day oral leucovorin (L) for 14 days. The CT was administered at outpatient clinics for 14\u2010day cycles. PTL was initiated with the intent of organ preservation and it was continued for a maximum of six cycles before locoregional therapy. Reevaluation after three cycles led to the termination of CT when the response was less than a partial response. CT was discontinued immediately upon evidence of tumor progression or excessive toxicity.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>From March 1996 through July 1999, 97 patients were enrolled consecutively. All participants were men with a median age of 56 years (range, 37\u201370 years). The primary tumor sites were the tongue base, 14, and the hypopharynx, 83. Sixteen percent of the tumors were Stage III, 84% were Stage IV, 62% were Stage T4, and 44% were Stage N2\u20103. The median number of CT cycles was six. On an intent\u2010to\u2010treat basis, 26 patients (27%) achieved complete responses and 32 patients (33%) achieved partial responses. The overall response rate was 60% (95% confidence interval, 50\u201370%). The most common toxicities of WHO Grade 3 or higher included (percent of patients): anemia, 8.3%; stomatitis, 6.3%; thrombocytopenia, 3.1%; and vomiting, 3.1%. With a median follow\u2010up period of 3 years, the overall survival and disease\u2010free survival rates were 40% and 38%, respectively. Organ preservation was achieved in 70% (29 of 37) of the surviving patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION<\/jats:title><jats:p>The outpatient PTL regimen was a moderately effective and minimally toxic CT for SCCHN. PTL should be studied further in combination with other active agents or radiotherapy for patients with SCCHN. Cancer 2002;94:2989\u201395. \u00a9 2002 American Cancer Society.<\/jats:p><jats:p>DOI 10.1002\/cncr.10570<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.10570","type":"journal-article","created":{"date-parts":[[2002,8,25]],"date-time":"2002-08-25T19:29:46Z","timestamp":1030303786000},"page":"2989-2995","source":"Crossref","is-referenced-by-count":59,"title":["Cisplatin, tegafur, and leucovorin"],"prefix":"10.1002","volume":"94","author":[{"given":"Hung\u2010Ming","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng\u2010Su","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jen\u2010Shi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I\u2010How","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun\u2010Ta","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tung\u2010Chieh Joseph","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,5,23]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/88.13.855"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/86.4.250"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199106133242402"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/88.13.890"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.5.946"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/hed.2880160109"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.3.671"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/86.4.265"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-199910000-00013"},{"key":"e_1_2_5_11_2","first-page":"87","article-title":"Cisplatin and 5\u2010Fluorouracil as neoadjuvant chemotherapy: predicting response in head and neck squamous cell cancer","volume":"94","author":"Wang HM","year":"1995","journal-title":"J Formos Med Assoc."},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0305-7372(80)80037-5"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.6.1303"},{"key":"e_1_2_5_14_2","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1200\/JCO.1989.7.4.425","article-title":"A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid\u2010Atlantic Oncology Program study","volume":"7","author":"Lokich J","year":"1998","journal-title":"J Clin Oncol."},{"key":"e_1_2_5_15_2","first-page":"981","article-title":"Tissue concentration of tegafur suppository in patients with head and neck cancer \u2014 concentration of 5\u2010FU in cancer tissue","volume":"21","author":"Koja S","year":"1994","journal-title":"Jpn J Cancer Chemother."},{"key":"e_1_2_5_16_2","first-page":"2093","article-title":"A phase II study of Futraful suppository in head and neck cancer","volume":"15","author":"Ohyama M","year":"1988","journal-title":"Jpn J Cancer Chemother."},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-199008000-00009"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-199008000-00001"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.9.3100"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.7.1656"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19890315)63:6 <1018::AID-CNCR2820631305>3.0.CO;2-S"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/83.24.1806"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1159\/000227451"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.1-1-107"},{"key":"e_1_2_5_25_2","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1200\/JCO.1985.3.8.1105","article-title":"High\u2010dose versus low\u2010dose cisplatin in advanced head and neck squamous carcinoma: a randomized study","volume":"3","author":"Veronesi A","year":"1985","journal-title":"J Clin Oncol."},{"volume-title":"American Joint Committee on Cancer: manual for staging of cancer","year":"1992","author":"Beahrs OH","key":"e_1_2_5_26_2"},{"key":"e_1_2_5_27_2","unstructured":"Department of Health the Executive Yuan R.O.C. December 2000: Cancer registry: annual report in Taiwan area 1997[in Chinese]."},{"key":"e_1_2_5_28_2","first-page":"876","volume-title":"Comprehensive management of head and neck tumors","author":"Thawley SE","year":"1999"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.3.838"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1995.17"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2715"},{"issue":"4","key":"e_1_2_5_32_2","first-page":"13","article-title":"The role of induction chemotherapy in the curative treatment of squamous cell cancer of the head and neck","volume":"27","author":"Posner MR","year":"2000","journal-title":"Semin Oncol."},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00255750"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.7.2557"},{"key":"e_1_2_5_35_2","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1200\/JCO.1992.10.6.1007","article-title":"Patient compliance with oral chemotherapy as assessed by novel electronic technique","volume":"10","author":"Rhoda Lee C","year":"1992","journal-title":"J Clin Oncol."},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-199404000-00009"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.3.1036"},{"key":"e_1_2_5_38_2","first-page":"1489","article-title":"Macrocytic anemia as a possible adverse effect of fluoropyrimidines","volume":"17","author":"Arai K","year":"1990","journal-title":"Jpn J Cancer Chemother."},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19930801)72:3<663::AID-CNCR2820720307>3.0.CO;2-V"},{"key":"e_1_2_5_40_2","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1182\/blood.V16.5.1535.1535","article-title":"Megaloblastic anemia associated with inhibition of thymine synthetasis (observations during 5\u2010fluorouracil treatment)","volume":"14","author":"Brennan MJ","year":"1960","journal-title":"Blood J."},{"key":"e_1_2_5_41_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.5.1672"},{"key":"e_1_2_5_42_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980601)82:11<2270::AID-CNCR24>3.0.CO;2-Q"},{"key":"e_1_2_5_43_2","first-page":"41","article-title":"A phase II trial of paclitaxel in squamous cell carcinoma of the head and neck with correlative laboratory studies","volume":"22","author":"Smith RE","year":"1995","journal-title":"Semin Oncol."},{"key":"e_1_2_5_44_2","first-page":"12","article-title":"Combination of taxanes with radiation: preclinical studies","volume":"9","author":"Milas L","year":"1999","journal-title":"Semin Radiat Oncol."},{"key":"e_1_2_5_45_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.11.3503"},{"key":"e_1_2_5_46_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.4.1096"},{"key":"e_1_2_5_47_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010715)92:2<326::AID-CNCR1326>3.0.CO;2-W"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.10570","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.10570","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T20:24:29Z","timestamp":1760300669000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.10570"}},"subtitle":["A moderately effective and minimally toxic outpatient neoadjuvant chemotherapy for locally advanced squamous cell carcinoma of the head and neck"],"short-title":[],"issued":{"date-parts":[[2002,5,23]]},"references-count":46,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2002,6]]}},"alternative-id":["10.1002\/cncr.10570"],"URL":"https:\/\/doi.org\/10.1002\/cncr.10570","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"type":"print","value":"0008-543X"},{"type":"electronic","value":"1097-0142"}],"subject":[],"published":{"date-parts":[[2002,5,23]]}}}